EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparative Efficacy of Neoadjuvant Endocrine Therapy, Neoadjuvant Chemotherapy, and Neoadjuvant Chemo‐Endocrine Therapy in Estrogen Receptor–Positive Breast Cancer Patients: A Meta‐Analysis

Yi Yuan, Ning Cui, Ziyi Xu, Chang Cui, Zongpeng Zhou, Zhefu Ma

The Breast Journal · 2025-01 · 2025 (1)

DOI: 10.1155/tbj/1670410 ↗
AbstractBibliografische Angaben

Abstract

Neoadjuvant therapy before surgery offers varying benefits as a well‐established treatment option for breast cancer. This study specifically evaluated the effectiveness of neoadjuvant endocrine therapy (NET), neoadjuvant chemotherapy (NCT), and neoadjuvant chemo‐endocrine therapy (NCET) in patients with estrogen receptor (ER)–positive breast cancer. This meta‐analysis was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Electronic searching was conducted to retrieve articles from databases including PubMed, Cochrane Library, EMBASE, CNKI, and Wanfang. The primary outcome measured by odds ratios (ORs) with 95% confidence intervals (CIs) focused on assessing pooled effect sizes. Random‐effects or fixed‐effect models were conducted according to the existence of statistical heterogeneity. A total of 15 eligible articles were included in the analysis. The results indicated clinical response (CR) (OR = 0.54; 95% CI = 0.41 to 0.73; I 2 = 39.6%) and clinical complete response (cCR) (OR = 0.31; 95% CI = 0.12 to 0.85; I 2 = 68.0%) after NET was significantly higher than NCT. However, no significant difference was shown in pathological complete response (pCR) (OR = 0.49; 95% CI = 0.23 to 1.04; I 2 = 0.0%) and breast‐conserving surgery (BCS) (OR = 0.49; 95% CI = 0.23 to 1.04; I 2 = 0.0%). The combined paradigm of NCET presented no significant improvement compared with monotherapy of NET or NCT. Overall, both NET and NCT are effective neoadjuvant treatment options for patients with ER+ breast cancer. More explicit clinical decision indicators need to be further clarified. And NCET does not offer additional benefits over NET or NCT in patients with ER+ breast cancer.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →